Search the Newsreel

Cellebrite Q2: This 33% Selloff Looks Like An Overreaction (NASDAQ:CLBT)

Cellebrite DI Ltd. (CLBT) experienced a significant 33% stock drop post-earnings, which the author believes is an overreaction. Despite missing Q2 guidance for ARR and revenue growth, and facing management transition and slower Inseyets conversions, the company maintains strong core products, high retention, and …

Cellebrite DI Releases Q2 2026 Financial Results

Cellebrite DI Ltd. reported mixed Q2 2026 financial results, with earnings per share meeting expectations at $0.11, while revenue of $131.1M slightly missed the $131.9M estimate. Despite the revenue miss, the company showed strong year-over-year growth, with total revenue up 16.0% and subscription services …

Accelerant Q2 Earnings Beat Estimates on Strong Premium Growth

Accelerant Holdings ARX reported second-quarter fiscal 2026 adjusted earnings of 32 cents per share, which more than doubled from 13 cents reported in the year-ago quarter. The bottom line beat the Zacks Consensus Estimate of 16 cents. Operating revenues increased 62.9% year over year …

Transcript : Turkcell Iletisim Hizmetleri A.S., Q2 2026 Earnings Call, Aug 13, 2026

Axcelis (ACLS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, August 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Senior Vice President and Interim Chief Financial Officer - David RyzhikPresident and CEO - Russell Low TAKEAWAYS Revenue -- $215.2 million, exceeding company forecasts due to stronger system …

AbCellera Biologics Inc. • Robinhood Token (ABCL) Price Prediction for 2026 to 2031

This article provides price predictions for AbCellera Biologics Inc. • Robinhood Token (ABCL) from 2026 to 2045, based on Bybit AI's analysis of user-driven Consensus Ratings and historical patterns. It forecasts a positive trend for ABCL's price, with significant potential ROI over the years, …

Cellectar Biosciences Releases Q2 2026 Financial Results

Cellectar Biosciences (CLRB) reported a wider-than-expected diluted loss of $0.57 per share for Q2 2026, missing analyst estimates. Despite this, the net loss of $6.9M represents an 83.2% improvement year-over-year. The clinical-stage biopharmaceutical company maintains strong analyst support for its oncology pipeline.

Celestica Inc Stock (CLS) Moved Up by 7.15% on Aug 13: Drivers Behind the Movement

Celestica Inc (CLS) stock rose by 7.15% on August 13th, outperforming its sector. This surge was primarily driven by strategic capital injection from a recent equity offering, strong operational execution with upgraded guidance, and favorable institutional and analyst commentary highlighting its crucial role in …

Turkcell Iletisim Hizmetleri Q2 Earnings Fall, Revenue Rises

Celestica Inc. (CLS) awards 190 D-RSUs to board director Colpitts

Celestica Inc. director Christopher W. Colpitts was granted 190 Director Restricted Share Units (D-RSUs) on August 11, 2026, as part of his equity-based compensation. These D-RSUs vest on May 20, 2027, bringing his directly held D-RSU balance to 1,000 units. Each D-RSU represents a …

Why is Accelerant Holdings stock surging today?

Accelerant Holdings stock surged 43.5% today after announcing a take-private deal with Thoma Bravo, valued at over $4 billion, and reporting a significant Q2 2026 earnings beat. The all-cash transaction offers shareholders a 49% premium to the previous day's closing price, with entities controlling …

Turkcell mobile base tops 40 million after 243,000 additions

Turkcell announced its Q2 2026 earnings, reporting consolidated revenues of TRY 71.8 billion, a 2.5% year-on-year increase, and an EBITDA of TRY 30.0 billion with a 41.8% margin. The company's mobile subscriber base exceeded 40 million for the first time, adding 243,000 subscribers in …

Turkcell Iletisim Hizmetleri: Second Quarter 2026 Results

Diversified and Resilient Business Model Delivers Steady Growth ISTANBUL, August 13, 2026--(BUSINESS WIRE)--Turkcell (NYSE:TKC) (BIST:TCELL): Please note that all financial data is consolidated and comprises that of Turkcell İletişim Hizmetleri A.S. (the "Company" or "Turkcell") and its subsidiaries and associates (together referred to as …

Turkcell Iletisim Hizmetleri A.S. Maintains Earnings Guidance for the Year 2026

Celcuity LLC (CELC) enters earnings with mixed weekly signals

A near-term rebound contrasts with deeper medium-term losses before the oncology biotech reports.

Accelerant Holdings stock Analysis: Post-Earnings Rally & Sustainability Check

Turkcell Iletisim Hizmetleri A.S. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Diversified and Resilient Business Model Delivers Steady Growth ISTANBUL, August 13, 2026--(BUSINESS WIRE)--Turkcell (NYSE:TKC) (BIST:TCELL): Please note that all financial data is consolidated and comprises that of Turkcell İletişim Hizmetleri A.S. (the "Company" or "Turkcell") and its subsidiaries and associates (together referred to as …

BioXcel Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against BioXcel Therapeutics, Inc. (NASDAQ: BTAI) and reminds investors of the September 5, 2023, deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit stems from allegations that BioXcel made …

Cellebrite DI Ltd. Stock Analysis: 5-Day Bearish Momentum Insights

Cellebrite DI Ltd. (CLBT) stock has crashed to $10.22 following a post-earnings decline, placing it deep in oversold territory according to its RSI readings across multiple timeframes. The company missed annual recurring revenue expectations due to delayed transactions and slower customer migration gains, leading …

Suzano: Strong Q2 results, resilient cash flow, and focus on cost control and deleveraging

Suzano S.A. (SUZB3) reported strong operational results and robust free cash flow in Q2 2026, alongside progress in Arbex integration. Despite global cost pressures, the company maintains its guidance for lower cash costs and deleveraging, anticipating efficiency gains in the second half of the …

Does Power‑Generating Carbon Capture Tech Shift the Bull Case for FuelCell Energy (FCEL)?

FuelCell Energy's new power-generating carbon capture technology, which integrates into plant exhaust streams to reduce emissions and produce electricity, reinforces the company's investment thesis. While this innovation offers potential for an additional revenue stream and scalability, the immediate impact on its financial picture remains …

Accelerant (NYSE:ARX) Shares Gap Up After Strong Earnings

Celcuity earnings loom as breast cancer drug approval fuels optimism By Investing.com

Cellebrite DI (NASDAQ:CLBT) Sets New 52-Week Low - Time to Sell?

Cellebrite DI (NASDAQ:CLBT) shares recently fell to a new 52-week low of $10.55, despite previously closing at $15.25. While insider selling totaling $2.48 million occurred over the last three months, analysts maintain a "Moderate Buy" consensus with an average price target of $21.80. Institutional …

Cellebrite DI Q2 Earnings Call Highlights

S&P 500-Titel United Parcel Service-Aktie: So viel hätten Anleger mit einem Investment in United Parcel Service von vor 10 Jahren verloren

Celcuity earnings loom as breast cancer drug approval fuels optimism

Celanese Corp SVP & General Counsel Acquires 600 Shares in Open Market Transaction

Ashley B. Duffie, Senior Vice President and General Counsel of Celanese Corp (NYSE:CE), purchased 600 shares of the company's common stock on August 11, 2026, at $45.6 per share. This open market transaction increases Duffie's direct ownership to 31,925 shares, with an additional 691.4868 …

Earnings call transcript: Cellectar narrows focus on WM as Q2 2026 loss widens

Cellectar Biosciences reported a wider-than-expected Q2 2026 loss of $0.57 per share, but its stock rose in premarket trading due to a stronger cash position and clinical progress for its lead drug, iopofosine I-131, in Waldenstrom’s macroglobulinemia (WM). The company secured up to $140 …

Accelerant Holdings (ARX) Reports Q2 Earnings: What Key Metrics Have to Say

Suzano S.A. (NYSE: SUZ) earnings: profit drops as cash flow stays strong

Suzano S.A. reported a significant drop in net income to R$1.8 billion in Q2 2026, down from R$5.0 billion a year earlier, primarily due to a weaker net financial result and higher costs. Despite this, the company maintained strong adjusted free cash flow of …

Cellebrite Appoints Shiven Ramji CEO as Company Sharpens Product Strategy

Cellebrite DI Ltd. has appointed Shiven Ramji as its new CEO, succeeding Thomas E. Hogan, to sharpen its product strategy with a focus on AI and new growth opportunities. Ramji, previously president of products and technology, will lead the company's expansion beyond digital forensics …

Earnings To Watch: Xcel Brands Inc (XELB) Q2 2026 -- GF Value Se

Xcel Brands Inc (XELB) is scheduled to release its Q2 2026 earnings on August 14, 2026, with revenue and earnings per share estimates showing recent declines. Analysts project an average target price of $4.00, implying a 292.16% upside, while GuruFocus's GF Value suggests an …

Suzano Posts Strong 2Q26 Cash Generation Despite Higher Costs and Rising Leverage

Dev Accelerator Posts Q1 FY27 Earnings Call Audio for Investor Access

Excel Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2026